Abstract
Paclitaxel (PTX) is a naturally occurring antineoplastic drug originally isolated from the bark of the Yew tree (Taxus bevifolia). It is currently used to treat various types of cancer, particularly in the M phase of cell division, where it blocks the functioning of the mitotic spindle by stabilizing the microtubules, which are responsible for giving the cell shape through the cytoskeleton. Commercially known as Taxol®, PTX has low solubility in water and is sold in Cremophor solution, which can cause several adverse reactions, such as peripheral neuropathy and hypersensitivity reactions. This study consisted of an analysis of the use of the antineoplastic drug PTX, addressing its adverse reactions, as well as its influence on the quality of life of breast cancer patients treated with this drug. The study was a quantitative, exploratory and cross-sectional study, through a bibliographic review and application of a questionnaire to 52 patients who use the drug paclitaxel, in various cycles of chemotherapy at the Municipal Hospital “Dr. Tabajara Ramos” in Mogi Guaçu. Of the participating patients, (50%) are over 51 years old and only (1.9%) are between 20 and 30 years old, (38.5%) of them had been in treatment for a longer time, (92%) reported having had some adverse reaction and only (8%) did not, (83%) reported bone pain and/or muscle pain, (50%) presented changes in the exam that precedes chemotherapy with the taxane. Only (4%) of the participants had an immediate allergic reaction to the intravenous application, (2%) the taxane administration was interrupted and could not be administered on the same day, (67%) had dermatological reactions, (60%) felt weak and needed to rest at home after the taxane administration, (83%) did not have lesions in the oral cavity, only (17%) did not have any. It is concluded that the majority of the participants had adverse reactions, and that they were not only nausea, vomiting, diarrhea and hair loss as most people think when dealing with chemotherapy.
Keywords: Chemotherapeutics. Breast cancer. Paclitaxel. Adverse drug reactions.
References
BONASSA, E. M. A.; GATO, M. I. R.; RODRIGUES, L. A. Terapêutica oncológica para enfermeiros e farmacêuticos. 5ª ed. 2023. Rio de Janeiro: Atheneu.
FRANCIOLI, A. L. S.; et al. Quimioterápicos utilizados no tratamento do câncer de mama. In: VII Mostra Interna de Trabalhos de Iniciação Científica, outubro de 2014.
GATO, M. I. R. et al. MOC – Drogas. Manual de oncologia clinica do brasil – Agentes oncológicos. 11ª ed. 2022. São Paulo: Dêndrix.
GOODMAN, L. S; GILMAN, A. As Bases Farmacológicas da Terapêutica. Porto Alegre: AMGH Ltda, 2019.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Atlas On-line de Mortalidade. Estimativa 2020: Incidência de Câncer no Brasil, RJ; 2019. Disponível em: <https://www.inca.gov.br/app/mortalidade>. Acesso em: 18. Jul. 2024.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação. Rio de Janeiro: INCA, 2019. Disponível em: <https://www.inca.gov.br/publicacoes/livros/situacao-do-cancer-de-mama-no-brasil-sintese-de-dados-dos-sistemas-de-informacao>. Acesso em: 18 julho 2024.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Estimativa 2023 Incidência de Câncer no Brasil, RJ 2022. Disponível em: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2023.pdf>. Acesso em: 18 Jul. 2024.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Incidência: Apresenta dados de incidência do câncer de mama no Brasil, regiões e estados. Rio de Janeiro. 2022. Disponível em: <https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-de-mama/dados-e-numeros/incidencia>. Acesso em: 31 Ago. 2024.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). . Dados e números sobre câncer de mama – relatório anual 2023. 2023. Disponível em: <https://www.inca.gov.br/publicacoes/relatorios/dados-e-numeros-sobre-cancer-de-mama-relatorio-anual-2023>. Acesso em 31 Ago. 2024.
LARA, J.; ADAMI, E. R. O uso dos taxanos para o tratamento do Câncer de Mama. Tópicos em Ciências da Saúde, v. 16. Belo Horizonte: Poisson, 2020. Disponível em: <https://www.poisson.com.br/livros/saude/volume16/Saude_vol16.pdf>. Acesso em: 22 jul. 2024.
OLIVEIRA, S. G. DE et al. Fotobiomodulação para o tratamento de Neuropatia Periférica Induzida por Paclitaxel: uma revisão integrativa. Brazilian Journal of Health Review, v. 6, n. 4, p. 19435–19465, 31 ago. 2023. Disponível em: <https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/62642/45081>. Acesso em: 31 Ago. 2024.
SILVA, R. O. L. Química Farmacêutica, Estabilidade e Manejo dos Medicamentos Oncológicos. 2013. São Paulo: Elsemer.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Amanda Cristina Negri Moreira, Tamires Alves dos Santos